Avalo Therapeutics Inc

:CERC   3:59:51 PM EDT
2.28
0.00 (0.00%)
Products

Cerecor Announces FDA Acceptance Of Investigational New Drug Application For Cerc-803 To Treat Leukocyte Adhesion Deficiency Type II

Published: 12/01/2020 12:32 GMT
(CERC) - Cerecor Announces FDA Acceptance of Investigational New Drug Application for Cerc-803 to Treat Leukocyte Adhesion Deficiency Type Ii.
Cerecor Inc - Plans to Initiate a Pivotal Trial of Cerc-803 in Lad-ii by First Half of 2021 and Anticipates Topline Data in Second Half of 2021.